Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
The Boston-based start-up Dewpoint Therapeutics has struck a partnership with Merck & Co. to develop drugs that treat HIV. Dewpoint is focused on developing new ways to drug biomolecular condensates, droplet-like structures of RNA, proteins, and other molecules inside cells that form through a physical process called liquid-liquid phase separation. The firm says these droplets hold secrets for new ways to make drugs for tough-to-treat and untreatable diseases. Dewpoint could receive up to $305 million in payments from Merck.
This article has been sent to the following recipient: